Development of second primary multiple myeloma five years after treatment for limited-stage small cell lung cancer: a rare case report
Abstract
Introduction. The development of a second primary malignancy (SPM) following small cell lung cancer (SCLC) has been previously reported in the literature. Especially smoking-related malignancy coupling is well known. The development of multiple myeloma (MM) in long-term survivors after treatment for SCLC is unknown. Here, we report the first case in the literature who developed MM 5 years after treatment for limited-stage SCLC.
Case report. A 67-year-old male patient was diagnosed with limited-stage SCLC. After he received chemotherapy and radiotherapy, he was followed up without medication. He was admitted to the hospital with back pain and dyspnea 5 years after the diagnosis of small cell lung cancer. MRI revealed osteolytic lesions in the vertebrae. Laboratory testing revealed a markedly elevated serum IgA and an elevated serum beta-2 microglobulin level. Serum immunofixation revealed IgA lambda-type M-protein. Lambda excretion in urine immunofixation electrophoresis was observed. Bone marrow aspiration revealed the frequency of plasma cells to be 80% of all nucleated cells. Hence, the final diagnosis revealed IgA lambda free light chain MM. Treatment was given for multiple myeloma. In the follow-up, the patient experienced increased dyspnea and developed bilateral pleural effusion. The cytology sent from thoracentesis sampling was reported as plasmocyte-rich material. The patient fell into a coma and died in an intensive care unit.
Conclusion. We presented the development of MM 5 years after treatment in a patient with SCLC who were treated for one year and then followed up with stable findings. It should be kept in mind that a patient with SCLC who is a long-term survivor and presents with back pain may have developed a primary malignancy originating from bone marrow rather than a bone metastasis. Patients should be advised smoking cessation after the treatment and diagnosis of SCLC. Also, the patients with SCLC who are long-term survivors should be closely monitored for the development of SPM.
Keywords: small cell lung cancermultiple myelomasecond primary malignancy
References
- Manapov F, Käsmann L, Roengvoraphoj O, et al. Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes. Lung Cancer (Auckl). 2018; 9: 49–55.
- Rajkumar S, Dimopoulos M, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncol. 2014; 15(12): e538–e548.
- Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001; 28(2 Suppl 4): 3–13.
- Hosoya Y, Gemma A, Seike M, et al. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer. 1999; 25(2): 87–93.
- Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am. 1992; 6(2): 225–247.
- López-Corral L, Gutiérrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011; 17(7): 1692–1700.
- Kawahara M, Ushijima S, Kamimori T, et al. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer. 1998; 78(3): 409–412.
- Jacoulet P, Depierre A, Moro D, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Française. Ann Oncol. 1997; 8(10): 1009–1014.
- Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997; 89(23): 1782–1788.
- Yoshida T, Matsui K, Masuda N, et al. [Risk of second primary cancer in two-year survivors of small cell lung cancer]. Nihon Kyobu Shikkan Gakkai Zasshi. 1996; 34(7): 741–746.
- Heyne KH, Lippman SM, Lee JJ, et al. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol. 1992; 10(10): 1519–1524.
- Lassen U, Osterlind K, Hansen M, et al. Radiotherapy of small cell lung cancer. An analysis with special reference to autopsy findings. Prog Clin Biol Res. 1985; 201(5): 141–152.
- Sagman U, Lishner M, Maki E, et al. Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol. 1992; 10(10): 1525–1533.
- Johnson DH, Porter LL, List AF, et al. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am J Med. 1986; 81(6): 962–968.
- Kono M, Allen PK, Lin SH, et al. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017; 12(11): 1696–1703.